Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.
作者信息
Luetkemeyer Anne F, Charlebois Edwin D, Hare C Bradley, Black Douglas, Smith Anna, Havlir Diane V, Peters Marion G
出版信息
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e96-9. doi: 10.1097/QAI.0b013e3182303937.
Abstract
摘要
相似文献
1
Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.合并感染人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV）且持续存在HBV病毒血症的成年患者的耐药模式及对恩替卡韦强化治疗的反应
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e96-9. doi: 10.1097/QAI.0b013e3182303937.
2
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.恩替卡韦用于接受拉米夫定作为抗逆转录病毒治疗一部分的HIV/HBV合并感染慢性乙肝患者的疗效和安全性。
AIDS. 2008 Sep 12;22(14):1779-87. doi: 10.1097/QAD.0b013e32830b3ab5.
3
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.替比夫定在体外对 HIV-1 临床分离株无抑制活性。
Antimicrob Agents Chemother. 2010 Jun;54(6):2670-3. doi: 10.1128/AAC.01703-09. Epub 2010 Mar 22.
4
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.管理乙型肝炎/艾滋病病毒合并感染：将恩替卡韦加入替诺福韦酯/恩曲他滨（富马酸替诺福韦二吡呋酯/恩曲他滨）已治疗患者。
AIDS. 2011 May 15;25(8):1051-6. doi: 10.1097/QAD.0b013e328345ef5e.
5
Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.HIV/乙肝病毒合并感染患者的乙肝病毒基因型及拉米夫定耐药突变
J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):557-61. doi: 10.1097/QAI.0b013e3180314b46.
6
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.恩替卡韦的抗HIV活性：对拉米夫定经治和初治患者的多中心评估。
AIDS. 2008 May 11;22(8):947-55. doi: 10.1097/QAD.0b013e3282ffde91.
7
Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.简短通讯：新诊断的HIV感染者中携带拉米夫定耐药突变的乙型肝炎病毒传播
AIDS Res Hum Retroviruses. 2009 Dec;25(12):1273-6. doi: 10.1089/aid.2009.0119.
8
[Entecavir: a new hope for the treatment of chronic hepatitis B].
Gastroenterol Hepatol. 2007 May;30(5):285-93. doi: 10.1157/13101981.
9
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.在同时感染 HIV 和乙型肝炎病毒的个体中，对基于替诺福韦的治疗反应不理想的模式和原因。
Clin Infect Dis. 2013 May;56(9):e87-94. doi: 10.1093/cid/cit002. Epub 2013 Jan 11.
10
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.替诺福韦为基础的联合治疗方案用于 HIV/HBV 合并感染：在 HIV 病毒血症不可检测的患者中，与 HBV 病毒学部分应答相关的因素。
AIDS. 2013 Jun 1;27(9):1443-8. doi: 10.1097/QAD.0b013e32836011c2.
引用本文的文献
1
Entecavir for children and adults with chronic hepatitis B.恩替卡韦用于治疗慢性乙型肝炎儿童及成人。
Cochrane Database Syst Rev. 2025 Apr 22;4(4):CD015536. doi: 10.1002/14651858.CD015536.pub2.
2
Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression.在 HIV/乙型肝炎共感染患者中，具有不同病毒抑制效果的累积替诺福韦暴露情况。
Clin Infect Dis. 2024 Sep 26;79(3):705-708. doi: 10.1093/cid/ciae241.
本文引用的文献
1
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.在慢性乙型肝炎病毒单感染患者中，接受替诺福韦酯富马酸二吡呋酯治疗长达 144 周后，未检测到耐药性。
Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22.
2
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.管理乙型肝炎/艾滋病病毒合并感染：将恩替卡韦加入替诺福韦酯/恩曲他滨（富马酸替诺福韦二吡呋酯/恩曲他滨）已治疗患者。
AIDS. 2011 May 15;25(8):1051-6. doi: 10.1097/QAD.0b013e328345ef5e.
3
Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.慢性乙型肝炎病毒感染的 HIV 患者长期使用核苷（酸）类似物的临床和病毒学结局。
AIDS. 2011 Jan 2;25(1):73-9. doi: 10.1097/QAD.0b013e328340fde2.
4
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.长期替诺福韦治疗对同时感染人类免疫缺陷病毒和乙型肝炎病毒的患者有效。
Gastroenterology. 2010 Dec;139(6):1934-41. doi: 10.1053/j.gastro.2010.08.045. Epub 2010 Aug 26.
5
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.在接受替诺福韦治疗的HIV-乙肝病毒合并感染患者中筛选出的HBsAg阴性乙肝病毒突变体的分子分析
AIDS. 2009 Jan 14;23(2):268-72. doi: 10.1097/QAD.0b013e3283224316.
6
EASL Clinical Practice Guidelines: management of chronic hepatitis B.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎的管理
J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29.
7
Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir.
J Antimicrob Chemother. 2008 Sep;62(3):626-7. doi: 10.1093/jac/dkn207. Epub 2008 May 8.
8
Risk and predictors of mortality associated with chronic hepatitis B infection.慢性乙型肝炎感染相关的死亡风险及预测因素
Clin Gastroenterol Hepatol. 2007 Aug;5(8):921-31. doi: 10.1016/j.cgh.2007.06.015.
9
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.基于循环乙肝病毒载量水平预测肝硬化风险。
Gastroenterology. 2006 Mar;130(3):678-86. doi: 10.1053/j.gastro.2005.11.016.
10
Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV.乙肝病毒基因型在与HIV合并感染时肝纤维化中的主要作用。
AIDS. 2006 Feb 14;20(3):419-27. doi: 10.1097/01.aids.0000200537.86984.0e.
Zotero 插件